Cardiovascular Peptides in Research: Natriuretic Peptides, RAAS Modulators, and Cardioprotective Mechanisms 2026

Cardiovascular Peptides | 2026-08-25 | 14 min read

2026 comprehensive guide to cardiovascular peptides: ANP, BNP, CNP, ACE2/Ang-(1-7) axis, apelin,ADM, and cardioprotective mechanisms for heart failure and cardiovascular disease.

Introduction: Cardiovascular Peptide Biology

Cardiovascular peptides regulate blood pressure, fluid balance, cardiac function, and vascular health. Understanding these systems is essential for cardiovascular disease research and therapeutic development.

This 2026 guide covers natriuretic peptides, RAAS modulators, and emerging cardiovascular peptide therapeutics.

Natriuretic Peptide System

Peptide Family

Members and Characteristics | Peptide | Length | Source | Primary Receptor | |---------|--------|--------|-----------------| | ANP | 28 aa | Atria | NPR-A | | BNP | 32 aa | Ventricles | NPR-A | | CNP | 22 aa | Endothelium | NPR-B | | DNP | 38 aa | Nerve | NPR-A |

ANP (Atrial Natriuretic Peptide)

Biology

• 28 amino acid peptide
• Stored in atrial granules
• Secreted in response to:
• Atrial stretch
• Volume overload
• Exercise

Cardiovascular Effects

| Effect | Mechanism | |--------|-----------| | Vasodilation | Direct smooth muscle, NO | | Natriuresis | Increased GFR, decreased reabsorption | | Diuresis | Inhibits ADH | | RAAS inhibition | Reduces renin, aldosterone | | Sympathetic inhibition | CNS effects |

BNP (Brain Natriuretic Peptide)

Biology

• 32 amino acid peptide
• Ventricular myocytes produce BNP
• Expression increased by:
• Volume overload
• Wall stress
• Hypoxia

Clinical Use

• Nesiritide (recombinant hBNP)
• Acute decompensated heart failure
• Hemodynamic improvement

Biomarker Role | Marker | Use | |--------|-----| | BNP | Diagnosis, prognosis | | NT-proBNP | More stable, same utility | | Dynamic changes | Treatment guidance |

CNP (C-Type Natriuretic Peptide)

Characteristics

• 22 amino acid peptide
• Produced by endothelium
• Paracrine signaling
• Does not cross the heart

Cardioprotective Effects | Effect | Evidence | |--------|----------| | Anti-fibrosis | Reduced cardiac remodeling | | Anti-proliferation | VSMC growth inhibition | | Angiogenesis | Endothelial protection | | Anti-inflammation | Reduced cytokines |

Renin-Angiotensin-Aldosterone System

Classical vs. Protective Arms

Classical RAAS (Pathological)

• Angiotensinogen → Angiotensin I (renin)
• Angiotensin I → Angiotensin II (ACE)
• Angiotensin II effects:
• Vasoconstriction
• Aldosterone release
• Cardiac hypertrophy
• Fibrosis
• Inflammation

ACE2/Ang-(1-7)/Mas Axis (Protective)

• Angiotensin II → Angiotensin-(1-7) (ACE2)
• Angiotensin-(1-7) → Mas receptor activation
• Protective effects:
• Vasodilation (NO)
• Anti-fibrosis
• Anti-hypertrophy
• Baroreflex improvement

ACE2 and Angiotensin Peptides

ACE2 Biology

Enzyme Function | Substrate | Product | Effect | |-----------|---------|--------| | Angiotensin II | Ang-(1-7) | Protective | | Angiotensin I | Ang-(1-9) | Less active | | Apelin | Apelin fragments | Variable |

Angiotensin-(1-7)

Peptide Sequence

• Asp-Arg-Val-Tyr-Ile-His-Pro
• 7 amino acid residues
• Multiple forms in circulation

Therapeutic Potential | Strategy | Approach | |----------|----------| | ACE2 recombinant | APN01 (in trials) | | Ang-(1-7) analogs | Stabilized peptides | | Mas agonists | Small molecule, peptides | | ACE2 activators | Natural compounds |

Apelin-APJ System

Apelin Peptides

Forms | Peptide | Length | Activity | |---------|--------|----------| | Apelin-13 | 13 aa | Highest activity | | Apelin-17 | 17 aa | Intermediate | | Apelin-36 | 36 aa | Full-length, lower potency |

APJ Receptor

• G-protein coupled receptor
• Gi/o signaling
• β-arrestin recruitment

Cardiovascular Effects

| Effect | Mechanism | |--------|-----------| | Vasodilation | NO-dependent | | Positive inotropy | cAMP, Ca²⁺ | | Diuresis | Aquaresis | | Anti-fibrosis | TGF-β inhibition | | Angiogenesis | VEGF synergy |

Adrenomedullin (ADM)

ADM Biology

Peptide Structure

• 52 amino acid peptide
• Produced by:
• Endothelium
• Cardiomyocytes
• Adrenal medulla

Receptors

• CLR + RAMP2/RAMP3 complexes
• Calcitonin gene-related peptide (CGRP) family

Cardiovascular Effects

| Effect | Clinical Relevance | |--------|-------------------| | Vasodilation | Blood pressure regulation | | Positive inotropy | Cardiac function | | Diuresis/natriuresis | Fluid balance | | Anti-fibrosis | Cardiac remodeling | | Baroreflex | Blood pressure control |

Emerging Therapeutics

Natriuretic Peptide Analogs

Modified Peptides | Peptide | Modifications | Advantages | |---------|--------------|------------| | CD-NP (Cenderitide) | Engineered | Enhanced activity, longer t½ | | plb-NP | Bacterial expression | Reduced cost | | NPA7 | Backbone modifications | Stabilized | | PL-3994 | NPR-A selective | Reduced hypotension |

ACE2/Ang-(1-7) Approaches

Clinical Development | Agent | Type | Stage | |-------|------|-------| | APN01 | rhACE2 | Phase 2 (COVID-19) | | Ang-(1-7) analogs | Peptide | Preclinical | | Mas agonists | Small molecule | Early development |

Novel Targets

| Target | Peptide Approach | |--------|-----------------| | Apelin | Apelin analogs, APJ modulators | | Adrenomedullin | ADM analogs, receptor modulators | | Urocortin | Peptide fragments | | Cortistatin | Synthetic analogs |

Heart Failure Research

Biomarkers

Diagnostic Peptides | Marker | Characteristics | |--------|-----------------| | NT-proBNP | Stable fragment, commercial assays | | BNP | Active hormone, rapid clearance | | MR-proADM | Stable mid-regional fragment |

Therapeutic Targets

Current Approaches | Target | Drug Class | Example | |--------|------------|---------| | NPR-A | Natriuretic peptides | Nesiritide | | NPR-A + NPR-B | Engineered NPs | CD-NP | | RAAS | ACE inhibitors, ARBs | Standard care | | SGLT2 | Non-peptide | Empagliflozin |

Emerging Peptide Targets

• Novel natriuretic analogs
• ACE2 activators
• Apelin agonists
• ADM modulators

Research Methods

Peptide Measurement

Immunoassays | Peptide | Assay | Sample | |---------|-------|--------| | ANP | RIA, ELISA | Plasma | | BNP/NT-proBNP | CLIA, ECLIA | Plasma, serum | | CNP | ELISA | Plasma, tissue | | Apelin | ELISA | Plasma |

Challenges

• Rapid degradation
• Diurnal variation
• Renal function effects
• Assay standardization

Functional Studies

In Vitro | Study | Endpoint | |-------|----------| | Cardiomyocyte | Contractility, survival | | Endothelial cells | NO production | | Fibroblasts | Proliferation, collagen | | VSMCs | Migration, proliferation |

In Vivo | Model | Applications | |-------|--------------| | Pressure overload | Cardiac hypertrophy | | Volume overload | Heart failure | | Ischemia-reperfusion | Cardioprotection | | Transgenic models | Mechanism studies |

Conclusion

Cardiovascular peptides represent a sophisticated system for regulating heart and vascular function. Key insights include:

• Natriuretic peptides offer cardioprotective effects
• ACE2/Ang-(1-7) axis is the protective arm of RAAS
• Apelin/APJ signaling has multiple cardiovascular benefits
• Therapeutic exploitation requires peptide stabilization
• Biomarkers (BNP, NT-proBNP) guide clinical management

Future developments will focus on:

• Stabilized peptide analogs
• Novel delivery systems
• Combination approaches
• Personalized medicine

ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.